Antibody to acetylcholine receptor in myasthenia gravis
Prevalence, clinical correlates, and diagnostic value
Abstract
Elevated amounts of antibodies specific for acetylcholine receptors were detected in 87 percent of sera from 71 patients with myasthenia gravis but not in 175 sera from individuals without myasthenia gravis, including those with other neurologic or autoimmune diseases. Antireceptor antibodies were not directed at the acetylcholine binding site of the receptor. Presence or titer of antibody did not appear to correlate with age, sex, steroid therapy, or duration of symptoms. Myasthenia gravis patients with only ocular symptoms had lower antibody titers, while the majority of titers in myasthenia gravis patients with thymoma exceeded the median titer of the myasthenia gravis group as a whole. Assay of antireceptor antibody should prove a useful test in the diagnosis of myasthenia gravis.
Get full access to this article
View all available purchase options and get full access to this article.
Information & Authors
Information
Published In
Copyright
© 1976 by the American Academy of Neurology.
Publication History
Published online: November 1, 1976
Published in print: November 1976
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Astragaloside IV protects against autoimmune myasthenia gravis in rats via regulation of mitophagy and apoptosis, Molecular Medicine Reports, 30, 1, (2024).https://doi.org/10.3892/mmr.2024.13253
- Effects of Treatments Applied in Myasthenia Gravis on Gait: Review, İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi, 22, (459-467), (2024).https://doi.org/10.38079/igusabder.1321888
- Interpretable machine learning models for predicting short-term prognosis in AChR-Ab+ generalized myasthenia gravis using clinical features and systemic inflammation index, Frontiers in Neurology, 15, (2024).https://doi.org/10.3389/fneur.2024.1459555
- Prognosis of immune checkpoint inhibitor-induced myasthenia gravis: a single center experience and systematic review, Frontiers in Neurology, 15, (2024).https://doi.org/10.3389/fneur.2024.1372861
- Epidemiology of myasthenia gravis in the United States, Frontiers in Neurology, 15, (2024).https://doi.org/10.3389/fneur.2024.1339167
- Exploring the depths of IgG4: insights into autoimmunity and novel treatments, Frontiers in Immunology, 15, (2024).https://doi.org/10.3389/fimmu.2024.1346671
- Myasthenia Gravis Disease Diagnosis System, 2024 31st International Conference on Mixed Design of Integrated Circuits and System (MIXDES), (299-304), (2024).https://doi.org/10.23919/MIXDES62605.2024.10614011
- Analysis of events from sudden isolated dysarthria to diagnosis of myasthenic crisis: myasthenia gravis mimicking acute lacunar stroke—a case report, Journal of Medical Case Reports, 18, 1, (2024).https://doi.org/10.1186/s13256-024-04617-w
- Using jitter analysis with concentric needle electrodes to assess disease status and treatment responses in myasthenia gravis, Clinical Neurophysiology Practice, 9, (227-232), (2024).https://doi.org/10.1016/j.cnp.2024.06.004
- Myasthenia gravis, Neurologic Channelopathies, (185-203), (2024).https://doi.org/10.1016/B978-0-323-90820-7.00006-9
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.